Ross A. Abrams, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Agreement Among RTOG Sarcoma Radiation Oncologists in Contouring Suspicious Peritumoral Edema for Preoperative Radiation Therapy of Soft Tissue Sarcoma of the Extremity.
   Bahig H, Roberge D, Bosch W, Levin W, Petersen I, Haddock M, Freeman C, Delaney TF, Abrams RA, Indelicato DJ, Baldini EH, Hitchcock Y, Kirsch DG, Kozak KR, Wolfson A, Wang D.
   Int J Radiat Oncol Biol Phys. 2013
   2013 Mar 5. doi:pii: S0360-3016(13)00128-4. 10.1016/j.ijrobp.2013.01.032. [Epub ahead of print]
   
2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
   Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.
   Lancet Oncol. 2013
   2013 Apr
   14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.
   
3. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.
   Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB 3rd, Macdonald J, Willett CG.
   Int J Radiat Oncol Biol Phys. 2012
   2012 Nov 1
   84(3):e291-7. doi: 10.1016/j.ijrobp.2012.04.035. Epub 2012 Jun 9.
   
4. Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma.
   Abrams RA.
   Cancer J. 2012
   2012 Nov
   18(6):624-32. doi: 10.1097/PPO.0b013e3182758c84.
   
5. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer.
   Goodman KA, Regine WF, Dawson LA, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA.
   Int J Radiat Oncol Biol Phys. 2012
   2012 Jul 1
   83(3):901-8. doi: 10.1016/j.ijrobp.2012.01.022. Epub 2012 Apr 5.
   
6. Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu.
   Garg S, Abrams RA, Leslie WT.
   Gastrointest Cancer Res. 2012
   2012 Jul
   5(4):135-6. No abstract available.
   
7. Supportive Care Considerations During Concurrent Chemoradiotherapy for Pancreatic Adenocarcinoma: Lessons Learned From Clinical Experience.
   Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ.
   Am J Clin Oncol. 2012
   2012 Jan 10. [Epub ahead of print]
   
8. Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study.
   Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E.
   Int J Radiat Oncol Biol Phys. 2012
   2012 Dec 19. doi:pii: S0360-3016(12)03817-5. 10.1016/j.ijrobp.2012.11.020. [Epub ahead of print]
   
9. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
   Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM.
   Int J Radiat Oncol Biol Phys. 2012
   2012 Dec 1
   84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27.
   
10. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.
    Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Aug 1
    83(5):1355-64. doi: 10.1016/j.ijrobp.2011.11.050.
    
11. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?
    Abrams RA.
    Expert Rev Gastroenterol Hepatol. 2012
    2012 Apr;6(2):149-61. Review.
    6(2):149-61. Review.
    
12. A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity.
    Yao R, Bernard D, Turian J, Abrams RA, Sensakovic W, Fung HC, Chu JC.
    Med Phys. 2012
    2012 Apr;39(4):2239-48.
    39(4):22
    
13. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.
    Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG.
    Int J Radiat Oncol Biol Phys.
    2011 Sep 1
    81(1):218-24
    
14. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG.
    Ann Surg Oncol.
    2011 May
    18(5):1319-26
    
15. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P.
    J Thorac Oncol.
    2011 Jun
    6(6):1079-86.
    
16. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
    Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D
    Ann Surg
    2011 Jan 6
    
17. Failure to Adhere to Protocol Specified Radiation Therapy Guidelines was Associated with Decreased Survival in RTOG 9704-A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients with Resected Adenocarcinoma of the Pancreas
    Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG
    Int J Radiat Oncol Biol Phys
    2011 Jan 28
    
18. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial
    Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW; American College of Surgeons Oncology Group
    Ann Surg Oncol
    2011 Feb
    18(2):337-44
    
19. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
    Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group.
    Ann Oncol. 2011
    2011 Feb
    22(2):348-54. doi: 10.1093/annonc/mdq384. Epub 2010 Jul 29.
    
20. Radiation therapy for heterotopic ossification prophylaxis afer high-risk elbow surgery.
    Strauss JB, Wysocki RW, Shah A, Chen SS, Shah AP, Abrams RA, Cohen MS.
    Am J Orthop (Belle Mead NJ).
    2011 Aug
    40(8):400-5.
    
21. The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704
    Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, Macdonald JS, Willett CG
    Int J Radiat Oncol Biol Phys
    2010 Oct 7
    
22. Weight Gain in Advanced Non-Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy is Associated With Superior Survival
    Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP
    Int J Radiat Oncol Biol Phys
    2010 Oct 5
    
23. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.
    Kasamon YL, Jones RJ, Brodsky RA, Fuchs EJ, Matsui W, Luznik L, Powell JD, Blackford AL, Goodrich A, Gocke CD, Abrams RA, Ambinder RF, Flinn IW.
    Ann Oncol. 2010
    2010 Jun
    21(6):1203-10. doi: 10.1093/annonc/mdp484. Epub 2009 Oct 30.
    
24. Variation in post-surgical lumpectomy cavity volume with delay in initiation of breast irradiation because of chemotherapy
    Strauss JB, Gielda BT, Chen SS, Shah AP, Abrams RA, Griem KL
    Int J Radiat Oncol Biol Phys
    2010 Jul 1
    77(3):831-5
    
25. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients
    Marsh JC, Herskovic AM, Gielda BT, Hughes FF, Hoeppner T, Turian J, Abrams RA
    Int J Radiat Oncol Biol Phys
    2010 Feb 1
    76(2):504-12
    
26. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer
    Shah AP, Strauss JB, Abrams RA
    Am J Clin Oncol
    2010 Feb
    33(1):101-6
    
27. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
    Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D
    Ann Surg
    2010 Dec 17
    
28. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis
    Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V
    Cancer
    2010 Apr 1
    116(7):1674-80
    
29. Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches
    Marsh JC, Gielda BT, Herskovic AM, Abrams RA
    J Oncol
    2010
    2010:198208
    
30. Evaluation of four volume-based image registration algorithms
    Zhang Y, Chu JC, Hsi W, Khan AJ, Mehta PS, Bernard DB, Abrams RA
    Med Dosim
    2009 Winter
    34(4):317-22
    
31. Application of holographic display in radiotherapy treatment planning II: a multi-institutional study
    Chu JCh, Gong X, Cai Y, Kirk MC, Zusag TW, Shott S, Rivard MJ, Melhus CS, Cardarelli G, Hurley A, Hepel JT, Napoli J, Stutsman S, Abrams RA
    J Appl Clin Med Phys
    2009 May 28
    10(3):2902
    
32. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas
    Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJ, Willett CG, Kachnic LA
    Int J Radiat Oncol Biol Phys
    2009 Jul 1
    74(3):824-30
    
33. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement
    Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW
    Ann Surg Oncol
    2009 Jul
    16(7):1751-6
    
34. Cholangiocarcinoma--what level of evidence should we have?
    Abrams RA
    Int J Radiat Oncol Biol Phys
    2009 Jan 1
    73(1):1-2
    
35. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer
    Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR
    Gastroenterology
    2009 Jan
    136(1):187-95
    
36. Management of a patient with borderline resectable pancreatic cancer. Case report and review
    Shah AP, Strauss JB, Leslie WT, Shah A, Mahon B, Abrams RA
    Oncology (Williston Park)
    2008 Nov 30
    22(13):1524-9
    
37. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA
    JAMA
    2008 Mar 5
    299(9):1019-26
    
38. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital
    Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R
    J Clin Oncol
    2008 Jul 20
    26(21):3503-10
    
39. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704
    Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG
    J Clin Oncol
    2008 Dec 20
    26(36):5918-22
    

• To watch a brief video of Ross Abrams, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• No one walks in off the street to a radiation oncologist and says, “I think I need a few rounds today.” So patients come in having seen other doctors. And they have some idea of why they’re being sent for consideration of radiation oncology as part of their management. It depends on why they’re being sent. Often they’re being sent as part of a program that’s intended to cure them of a serious and threatening illness. Sometimes they’re being sent to get relief of a significant source of discomfort related to a serious illness.

  I meet them where they’re at and listen carefully, engage them as human beings. And I take the fact that I have the opportunity to spend time with them as a wonderful opportunity to help the human being — who has a problem that brings them to me — because I’m specifically trained and interested in helping with that problem.